Tecovirimat at a crossroads: What the PALM007 trial tells us.

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-08-08 DOI:10.1016/j.medj.2025.100779

Olivier Segeral, Yazdan Yazdanpanah, Alexandra Calmy

引用次数: 0

Abstract

The double-blind, randomized, placebo-controlled PALM007 trial did not report any significant differences between placebo and tecovirimat regarding the time-to-lesion resolution or the virological clearance for the treatment of clade I Mpox virus infection in the Democratic Republic of Congo.¹ We discuss how these results compare with other clinical trials and what lessons can be drawn for future therapeutics strategies.

查看原文本刊更多论文

站在十字路口的替科维莫：PALM007试验告诉我们的。

在刚果民主共和国，双盲、随机、安慰剂对照的PALM007试验未报告安慰剂和替科virimat在治疗I支Mpox病毒感染的病变缓解时间或病毒学清除方面有任何显著差异。我们将讨论这些结果如何与其他临床试验进行比较，以及可以为未来的治疗策略吸取哪些教训。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.